SLC19A2 and Thiamine-responsive megaloblastic anemia: The latter can be achieved via administration of pharmacological doses of thiamin [as done in the treatment of conditions like Thiamin-Responsive Megaloblastic Anemia [(an autosomal recessive disorder caused by a mutation in the SLC19A2); Lu et al., 2019] to force entry of thiamin into cells via simple diffusion (i.e., to by-pass the need for transport via the cell membrane carrier-mediated process).